Odyssey Therapeutics Inc (ODTX) FinancialsODTXFinancialOdyssey Therapeutics Inc

In the context of the broader market, ODTX competes directly with industry leaders such as SANA and GLUE. With a market capitalization of $996.25M, it holds a significant position in the sector. When comparing efficiency, ODTX's gross margin of N/A stands against SANA's N/A and GLUE's 100.00%. Such benchmarking helps identify whether Odyssey Therapeutics Inc is trading at a premium or discount relative to its financial performance.

Odyssey Therapeutics reported a total revenue of $1.91 million in Q1 2025, but has seen a decline in revenue with $0 reported in Q1 and Q2 of 2026. The company has also faced increasing net losses, with a reported loss of $52.8 million in Q2 2026, up from $41.2 million in the same quarter last year.